Nasdaq: TGTX−0.97% 24h move
Price before$39.20May 27, 2026, 4:00 PM ET
First trade after$39.20May 27, 2026, 5:23 PM ET
24h later$38.82May 28, 2026, 4:13 PM ET
Complete Announced during: After hours · announced Wed 4:34p ET (after hours); before = Wed close; first trade Wed 5:23p ET; time = SEC 8-K acceptance
TG Therapeutics (Nasdaq: TGTX) reported topline results from a Phase 3 trial of ublituximab in relapsing forms of multiple sclerosis on May 27, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- ublituximab
- Phase
- Phase 3
- Result
- Met endpointThe trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved initiation dosing regimen of 150 mg on Day 1 and 450 mg on Day 15 and a consolidated single 600 mg infusion on Day 1, eliminating the need for a Day 15 infusion.
- Sponsor
- TG Therapeutics Nasdaq: TGTX
- Dates
- Announced May 27, 2026, 4:34 PM ET (SEC 8-K filing time)
About this trial
This Phase 3 trial tested ublituximab in Relapsing Forms of Multiple Sclerosis. TG Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.